Loss of ADAM15 in female mice does not worsen pressure overload cardiomyopathy, independent of ovarian hormones.

Am J Physiol Heart Circ Physiol

Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Published: August 2024

AI Article Synopsis

  • * In experiments with female mice undergoing transverse aortic constriction (TAC), results showed ADAM15 loss did not significantly alter cardiac hypertrophy or dysfunction compared to wild-type mice, potentially due to the protective influence of estrogen.
  • * Findings suggest that ovarian hormone loss didn't fully mimic the male heart failure response, and the role of ADAM15 in TAC-related events appears less significant in females, highlighting the need for further research into sex-specific factors in cardiomyopathies.

Article Abstract

Cardiac hypertrophy is a common feature in several cardiomyopathies. We previously reported that loss of ADAM15 (disintegrin and metalloproteinase 15) worsened cardiac hypertrophy and dilated cardiomyopathy following cardiac pressure overload. Here, we investigated the impact of ADAM15 loss in female mice following cardiac pressure overload induced by transverse aortic constriction (TAC). Female Adam15 mice developed the same degree of cardiac hypertrophy, dilation, and dysfunction as the parallel female wild-type (WT) mice at 6 wk post-TAC. To determine if this is due to the protective effects of estrogen, which could mask the negative impact of loss, WT and mice underwent ovariectomy (OVx) 2 wk before TAC. Cardiac structure and function analyses were performed at 6 wk post-TAC. OVx similarly impacted females of both genotypes post-TAC. Calcineurin (Cn) activity was increased post-OVx-TAC, and more in mice; however, this increase was not reflected in the total-to-phospho-NFAT levels. Integrin-α expression, which was upstream of Cn activation in male -TAC mice, remained unchanged in female mice. However, activation of the mitogen-activated protein kinases (ERK, JNK, P38) was greater in -OVx-TAC than in WT-OVx-TAC mice. In addition, ADAM15 protein levels were significantly increased post-TAC in male but not in female WT mice. Myocardial fibrosis was comparable in non-OVx WT-TAC and -TAC mice. OVx increased the perivascular fibrosis more in compared with WT mice post-TAC. Our data demonstrate that loss of ovarian hormones did not fully replicate the male phenotype in the female mice post-TAC. As ADAM15 levels were increased in males but not in females post-TAC, it is plausible that ADAM15 does not play a prominent role in post-TAC events in female mice. Our findings highlight the significance of factors other than sex hormones in mediating cardiomyopathies in females, which require a more thorough understanding. Loss of ADAM15 in female mice, unlike the male mice, does not worsen the cardiomyopathy following cardiac pressure overload. Ovariectomy does not worsen the post-TAC cardiomyopathy in female mice compared with female WT mice. Lack of deleterious impact of deficiency in female mice is not because of the protective effects of ovarian hormones but could be due to a less prominent role of ADAM15 in cardiac response to post-TAC remodeling in female mice.

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpheart.00116.2024DOI Listing

Publication Analysis

Top Keywords

female mice
44
mice
20
pressure overload
16
female
13
loss adam15
12
ovarian hormones
12
cardiac hypertrophy
12
cardiac pressure
12
mice post-tac
12
post-tac
10

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!